Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinN (3)

ProteinS (1)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 3 records in total 3
    records per page




    The Prognostic Value of Myocardial Injury MESHD in COVID-19 MESHD Patients and Associated Characteristics

    Authors: jian he; Bicheng Zhang; Quan Zhou; Wenjing Yang; Jing Xu; Tingting Liu; Haijun Zhang; Zhiyong Wu; Dong Li; Qing Zhou; Jie Yan; Cuizhen Zhang; Robert G. Weiss; Guanshu Liu; Zhongzhao Teng; Arlene Sirajuddin; Haiyan Qian; Shihua Zhao; Andrew E. Arai; Minjie Lu; Xiaoyang Zhou

    doi:10.21203/rs.3.rs-251810/v1 Date: 2021-02-17 Source: ResearchSquare

    Background: Since December 2019, Coronavirus disease 2019 MESHD ( COVID-19 MESHD) has emerged as an international pandemic. COVID-19 MESHD patients with myocardial injury MESHD might need special attention. However, understanding on this aspect remains unclear. This study aimed to illustrate clinical characteristics and the prognostic value of myocardial injury MESHD to COVID-19 MESHD patients. Methods: This retrospective, single-center study finally included 304 hospitalized COVID-19 MESHD cases confirmed by real-time RT-PCR from January 11 to March 25, 2020. Myocardial injury MESHD was determined by serum high-sensitivity troponin I (Hs-TnI). The primary endpoint was COVID-19 MESHD associated mortality. Results: Of 304 COVID-19 MESHD patients (median age, 65 years; 52.6% males), 88 patients (27.3%) died (61 patients with myocardial injury MESHD, 27 patients without myocardial injury MESHD on admission). COVID-19 MESHD patients with myocardial injury MESHD had more comorbidities ( hypertension MESHD, chronic obstructive pulmonary disease MESHD, cardiovascular disease MESHD, and cerebrovascular disease MESHD); lower lymphocyte counts, higher C-reactive protein HGNC ( CRP HGNC, median, 84.9 vs 28.5 mg/L, p<0.001), procalcitonin levels (median, 0.29 vs 0.06 ng/ml, p<0.001), inflammatory and immune response markers; more frequent need for noninvasive ventilation, invasive mechanical ventilation; and was associated with higher mortality incidence (hazard ratio, HR=7.02, 95% confidence interval, CI, 4.45-11.08, p<0.001) than those without myocardial injury MESHD. Myocardial injury MESHD (HR=4.55, 95% CI, 2.49-8.31, p<0.001), senior age, CRP HGNC levels, and novel coronavirus pneumonia MESHD ( NCP PROTEIN) types on admission were independent predictors to mortality in COVID-19 MESHD patients. Conclusions: COVID patients with myocardial injury MESHD on admission is associated with more severe clinical presentation and biomarkers. Myocardial injury MESHD and higher HsTNI are both strongest independent predictors to COVID related mortality after adjusting confounding factors. In addition, senior age, CRP HGNC levels and NCP PROTEIN types are also associated with mortality. Trial registration: Not applicable.

    Proteome-wide analysis of differentially-expressed SARS-CoV-2 antibodies in early COVID-19 MESHD infection

    Authors: Xiaomei Zhang; Xian Wu; Dan Wang; Minya Lu; Xin Hou; Hongye Wang; Te Liang; Jiayu Dai; Hu Duan; Yingchun Xu; Yongzhe Li; Xiaobo Yu

    doi:10.1101/2020.04.14.20064535 Date: 2020-04-20 Source: medRxiv

    Rapid and accurate tests that detect IgM and IgG antibodies to SARS-CoV-2 proteins are essential in slowing the spread of COVID-19 MESHD by identifying patients who are infected with COVID-19 MESHD. Using a SARS-CoV-2 proteome microarray developed in our lab, we comprehensively profiled both IgM and IgG antibodies in forty patients with early-stage COVID-19 MESHD, influenza, or non-influenza who had similar symptoms. The results revealed that the SARS-CoV-2 N protein PROTEIN is not an ideal biomarker for COVID-19 MESHD diagnosis because of its low immunogenicity, thus tests that rely on this marker alone will have a high false negative rate. Our data further suggest that the S protein PROTEIN subunit 1 receptor binding domain (S1-RBD) might be the optimal antigen for IgM antibody detection, while the S protein PROTEIN extracellular domain (S1+S2ECD) would be the optimal antigen for both IgM and IgG antibody detection. Notably, the combination of all IgM and IgG biomarkers can identify 87% and 73.3% COVID-19 MESHD patients, respectively. Finally, the COVID-19 MESHD-specific antibodies are significantly correlated with the clinical indices of viral infection MESHD and acute myocardial injury MESHD (p[≤]0.05). Our data may help understand the function of anti-SARS-CoV-2 antibodies and improve serology tests for rapid COVID-19 MESHD screening.

    Acute Myocardial Injury of Patients with Coronavirus Disease 2019 MESHD

    Authors: Huayan Xu; Keke Hou; Hong Xu; Zhenlin Li; Huizhu Chen; Na Zhang; Rong Xu; Hang Fu; Ran Sun; Lingyi Wen; Linjun Xie; Hui Liu; Kun Zhang; Joseph B Selvanayagam; Chuan Fu; Shihua Zhao; Zhigang Yang; Ming Yang; Yingkun Guo

    doi:10.1101/2020.03.05.20031591 Date: 2020-03-08 Source: medRxiv

    Background: Since the outbreak of the Coronavirus Disease 2019 MESHD ( COVID-19 MESHD) in China, respiratory manifestations of the disease have been observed. However, as a fatal comorbidity, acute myocardial injury MESHD ( AMI MESHD) in COVID-19 MESHD patients has not been previously investigated in detail. We investigated the clinical characteristics of COVID-19 MESHD patients with AMI MESHD and determined the risk factors for AMI MESHD in them. Methods: We analyzed data from 53 consecutive laboratory-confirmed and hospitalized COVID-19 MESHD patients (28 men, 25 women; age, 19-81 years). We collected information on epidemiological and demographic characteristics, clinical features, routine laboratory tests (including cardiac injury MESHD biomarkers), echocardiography, electrocardiography, imaging findings, management methods, and clinical outcomes. Results: Cardiac complications were found in 42 of the 53 (79.25%) patients: tachycardia MESHD (n=15), electrocardiography abnormities (n=11), diastolic dysfunction MESHD (n=20), elevated myocardial enzymes (n=30), and AMI MESHD (n=6). All the six AMI MESHD patients were aged >60 years; five of them had two or more underlying comorbidities ( hypertension MESHD, diabetes MESHD, cardiovascular diseases MESHD, and chronic obstructive pulmonary disease MESHD). Novel coronavirus pneumonia MESHD ( NCP PROTEIN) severity was higher in the AMI MESHD patients than in patients with non-definite AMI MESHD (p<0.001). All the AMI MESHD patients required care in intensive care unit; of them, three died, two remain hospitalized. Multivariate analyses showed that C-reactive protein HGNC ( CRP HGNC) levels, NCP PROTEIN severity, and underlying comorbidities were the risk factors for cardiac abnormalities MESHD in COVID-19 MESHD patients. Conclusions: Cardiac complications MESHD are common in COVID-19 MESHD patients. Elevated CRP HGNC levels, underlying comorbidities, and NCP PROTEIN severity are the main risk factors for cardiac complications in COVID-19 MESHD patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.